Edap Tms SA
NASDAQ:EDAP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.36
8.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Edap Tms SA
Edap Tms SA
Cost of Revenue
Edap Tms SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cost of Revenue
-€36m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Biomerieux SA
PAR:BIM
|
Cost of Revenue
-€1.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Carmat SA
PAR:ALCAR
|
Cost of Revenue
-€35.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Biosynex SA
PAR:ALBIO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Cost of Revenue
-€789k
|
CAGR 3-Years
64%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cost of Revenue
-€21.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Edap Tms SA
Glance View
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.
See Also
What is Edap Tms SA's Cost of Revenue?
Cost of Revenue
-36m
EUR
Based on the financial report for Dec 31, 2023, Edap Tms SA's Cost of Revenue amounts to -36m EUR.
What is Edap Tms SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%
Over the last year, the Cost of Revenue growth was -16%. The average annual Cost of Revenue growth rates for Edap Tms SA have been -16% over the past three years , -10% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
